

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Hengrui Pharmaceuticals Co., Ltd.

江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the “**Company**”) had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
March 20, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Dong Jiahong, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Announcement in Relation to the Approval for Drug Registration

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Recently, Suzhou Suncadia Biopharmaceuticals Co., Ltd.(蘇州盛迪亞生物醫藥有限公司), a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd.(江蘇恒瑞醫藥股份有限公司) (the “Company”), received a notice from the National Medical Products Administration (NMPA). Approval was granted for the company’s self-developed Class 1 innovative drug, trastuzumab rezetecan for injection (SHR-A1811), for a new indication. The relevant information is hereby announced as follows:

I. Basic Information of the Drug

Common name of drug: Trastuzumab Rezetecan for Injection

Dosage Form: Injection

Strength: 0.1g/ bottle

Registered Category: Class 2.2 Therapeutic Biological Product

Registration Acceptance No.: CXSS2500094

Prescription/Non-prescription Drug: Prescription Drug

Approved indications: This product is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive breast cancer who have previously received one or more anti-HER2 therapies.

II. The Approved Indications of the Drug

The company's trastuzumab rezetecan for injection was approved for marketing in China in May 2025, indicated for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating HER2 (ERBB2) mutations who have previously received at least one systemic therapy.

III. Other Information of the Drug

Breast cancer ranks among the leading malignancies among women worldwide in terms of incidence and mortality^[1], posing a serious threat to female health. HER2-positive breast cancer accounts for approximately 15% – 20% of all breast cancers. Before the advent of anti-HER2 therapies, the average survival of patients with HER2-positive breast cancer was only half that of HER2-negative patients. The emergence of anti-HER2 therapies has greatly changed the disease course and treatment outcomes of HER2-positive breast cancer^[2]. However, there remains a significant unmet need in the treatment of HER2-positive advanced breast cancer, including limited drug options, early development of resistance, or adverse events that limit drug use. Clinically, there is an urgent need to explore regimens with high efficacy and good tolerability.

Trastuzumab rezetecan for injection can bind to and endocytose HER2-expressing tumor cells, release toxins through protease cleavage within the lysosomes of tumor cells, induce cell cycle arrest, and trigger tumor cell apoptosis. The toxins it releases have high membrane permeability and can exert a bystander killing effect, further enhancing the anti-tumor efficacy. Currently, similar products marketed in China include ado-trastuzumab emtansine developed by Roche, fam-trastuzumab deruxtecan jointly developed by AstraZeneca and Daiichi Sankyo, disitamab vedotin developed by RemeGen, and trastuzumab botidotin developed by Kelun-Biotech. According to the EvaluatePharma database, the total global sales of similar products in 2025 amounted to approximately USD 8.157 billion. To date, the total accumulated R&D investment in the trastuzumab rezetecan for injection related project is approximately RMB 1,888.3 million (unaudited).

IV. Risk Warning

The Company places great importance on drug R&D, and strictly controls the

quality and safety throughout the processes of drug R&D, manufacture, and sales. However, post-approval production and sales may be subject to uncertainties. Investors are kindly advised to make prudent decisions and pay attention to investment risks.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

March 20, 2026

[1]. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2024;74(3):229-263.

[2]. Martínez-Sáez O, Prat A. Current and Future Management of HER2-Positive Metastatic Breast Cancer. *JCO Oncol Pract*. 2021;17(10):594-604.